Prevention of hepatocellular carcinoma complicating chronic hepatitis C.
Chronic hepatitis C virus (HCV) infection accounts for most cases of hepatocellular carcinoma (HCC) in Japan and is the second major cause in many other countries. Development of HCC takes a considerable time after onset of HCV infection, between 20-40 years in most cases, and usually develops after cirrhosis is established. Although only a minority of HCV infections reach this stage, the high prevalence of chronic HCV infection in many countries (1-3%) is such that HCC related to HCV infection poses a significant public health issue 20-50 years after the onset of HCV epidemics. Due to advances in testing, and accessibility of clean, disposable medical apparatus including syringes and needles, and particularly screening of donor blood for anti-HCV and by nucleic acid testing, new cases of HCV infection have decreased in most countries, except for continued transmission by injection drug users (IDU). A key difference between HBV and HCV infection is that HCV can be eradicated by effective antiviral treatment. Sustained eradication of HCV reverses hepatic fibrosis, thereby preventing progression to cirrhosis and risk of HCC. Further, it has been well demonstrated that interferon-based antiviral therapy suppresses development of HCC in high-risk patients, particularly when sustained viral response (SVR) is obtained. In summary, the two key approaches to prevent development of HCV-related HCC are primary prevention of HCV infection (adequate programs to screen donor blood, universal precautions to stop medical transmission of blood-borne viruses, curbing transmission by IDU) and potent antiviral therapy of chronic HCV infection.
Ueno
Yoshiyuki
Y
Tohoku University Graduate School of Medicine, Division of Gastroenterology, 1-1 Seiryo, Aobaku, Sendai 980-8574, Japan. yueno@mail.tains.tohoku.ac.jp
Sollano
Jose D
JD
Farrell
Geoffrey C
GC
D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000517:prevention & control* / Q000821:virology; D018450:Disease Progression; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy* / Q000517:prevention & control* / Q000635:transmission; D006801:Humans; D008103:Liver Cirrhosis / Q000517:prevention & control* / Q000821:virology; D008113:Liver Neoplasms / Q000517:prevention & control* / Q000821:virology; D012307:Risk Factors; D016896:Treatment Outcome
D000998:Antiviral Agents